How Peptides Are Absorbed: The Bioavailability Problem

If peptides are so promising, why does almost every legitimate one arrive as an injection? The answer is not marketing or convenience. It is chemistry. Peptides are short chains of amino acids, and the human body is exceptionally good at taking those chains apart before they can do anything useful.

This is the bioavailability problem, and it shapes nearly everything about how peptide therapies are designed, priced, and sold.

What happens to a swallowed peptide

The gut is built to digest protein. Enzymes in the stomach and small intestine cut peptide bonds for a living, so an oral peptide is walking into a shredder. Even the fragments that survive face a second barrier: the intestinal wall is designed to let small molecules through while keeping larger ones out, and most peptides are simply too big and too water-loving to cross efficiently.

The result is that oral bioavailability for many peptides sits in the low single digits of a percent, sometimes less. A dose that works by injection can be almost completely wasted when swallowed.

The honest summary: for most peptides, “oral” and “effective” are hard to achieve at the same time. When a product promises both, that is a claim to scrutinize, not assume.

Oral semaglutide is the clearest worked example. As a 2020 review in Diabetes Therapy describes, even a purpose-built oral GLP-1 drug clears the gut only with help — and the absorbed fraction stays in the low single digits of a percent.

Why injection sidesteps the problem

It bypasses stomach and intestinal enzymes entirely.
It avoids first-pass metabolism in the liver.
Dosing is predictable, which matters for anything where the margin between “too little” and “too much” is narrow.

This is why so much real clinical peptide work, from older agents to the newer metabolic drugs, is delivered subcutaneously.

The exceptions, and what they cost

Oral peptides do exist, but the engineering bill is steep. Oral semaglutide is co-formulated with an absorption enhancer, SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), which buffers the low-pH microenvironment around the tablet to shield the peptide from gastric enzymes and increases its flux across the stomach lining. Even so, the Diabetes Therapy review notes the drug works only under tight conditions: swallowed whole on an empty stomach with up to about 120 mL of water, followed by at least a 30-minute fast before anything else, because food markedly disrupts its pharmacokinetics. The absorbed fraction is roughly 1% — and absorption varies considerably from person to person.

That context is useful when you scroll past an “oral peptide” capsule sold online with no such backing. The compound may be real. Whether a meaningful amount of it ever reaches your bloodstream is a separate question, and usually an unanswered one.

The takeaway

Peptides are fragile travelers in a hostile gut. Injection is the default for legitimate therapies because it is the route the biology allows, not because anyone prefers needles. Even a pharmaceutical-grade oral peptide like semaglutide needs a dedicated absorption enhancer and strict fasting rules to land roughly 1% of the dose. When you see an oral peptide capsule claim without absorption data, the fair default is skepticism.

What happens to a swallowed peptide

Why injection sidesteps the problem

The exceptions, and what they cost

The takeaway

Sources